Taisun Biotech Corrects Errors in Its Q1 2026 Consolidated Financial Report

1. Date of occurrence: 2026/05/20 2. Company name: Taisun Biotechnology Co., Ltd. 3. Relationship to the company (please enter 'this company' or 'subsidiary'): This company 4. Mutual shareholding ratio: Not applicable 5. Reason for occurrence: Incorrect positive/negative sign for "Interest expense" and "Interest paid" in the Q1 2026 Cash Flow Statement. Omission of "Interest income" and "Interest received". 6. Corrected information item/report name: Company's Q1 2026 consolidated financial report, Q1 2026 iXBRL filing information 7. Pre-correction amount/content/page: Cash Flow Statement Page 10 Jan 1, 2026 Jan 1, 2025 to Mar 31 to Mar 31 ---------------------------------------------------- Interest expense ( 166) ( 226) Interest paid 166 226 8. Post-correction amount/content/page: Cash Flow Statement Page 10 Jan 1, 2026 Jan 1, 2025 to Mar 31 to Mar 31 ---------------------------------------------------- Interest expense 166 226 Interest income ( 1,114) ( 1,121) Interest received 1,114 1,121 Interest paid ( 166)